Navigation Links
AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury
Date:7/2/2008

Biotech innovator develops new therapies based on cells manufactured from

bone marrow; SV Life Sciences and Novo A/S provide funding round

SALT LAKE CITY and HAMBURG, Germany, July 2 /PRNewswire/ -- AlloCure Inc., a biotechnology company at the forefront of innovative cell therapies for the treatment of acute kidney injury, today announced the closing of a $14.5MM Series A financing. The round was led by SV Life Sciences with Novo A/S joining the syndicate.

"This financing represents a significant step forward in developing the first cell therapy to effectively treat patients who are suffering from acute kidney injury," said John Wirthlin President and CEO. "SV Life Sciences and Novo Ventures bring tremendous depth, experience and clout to our efforts. We look forward to working closely with our investors to successfully commercialize this unique and proprietary technology."

Despite major advances over the past 30 years, acute kidney injury remains treatment resistant and presents a growing critical problem for a significant number of patients around the world.

"AlloCure has not only established itself as a leader in developing cell therapies to treat kidney patients," said Lutz Giebel, Managing Partner of SV Life Sciences. "They have also built an attractive and sound business model addressing this growing and unmet medical need."

The investment is key to furthering the company's promising progress in developing these groundbreaking treatments and entering clinical trials. The company hopes to offer acute kidney injury patients a safe and effective treatment option for this life threatening disease in the not too distant future.

"The AlloCure team has developed an impressive scientific foundation which has enabled it to obtain all the regulatory approvals necessary to begin its Phase I Clinical Trial," said Thomas Dyrberg, Senior Partner at Novo. "We anticipate that substantial clinical progress will be made ove
'/>"/>

SOURCE AlloCure Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 DuPont Pioneer and ... more than double the acreage contracted for Plenish® ... its soybean crush facility in Salisbury, Md. The ... will target several markets including foodservice and food ... performance. , For the 2015 growing season, Perdue ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 Today, Nerium ... announced the winners of its “Reflect Your Youth” contest, ... not only seen a difference in their skin since ... a new outlook on life as a result of ... originated as an effort by Nerium International to inspire ...
(Date:10/25/2014)... Great Barrington, MA (PRWEB) October 25, 2014 ... contamination control products, is pleased to announce the ... to achieve the highest level of contamination containment ... in ISO Class 3 and higher cleanroom environments, ... continuous filament polyester knit laundered wiper that continues ...
(Date:10/25/2014)... , Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: ... presented at the Fourth International Symposium on Thymosins in ... Italy.  "When thymosin beta 4 (TB4) ... into the peritoneal cavity in a rodent model of ... throughout the brain parenchyma (the functional tissue of the ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... article, the City of Milwaukee has negotiated a three-year "franchise-like" ... company to start an Internet protocol video service to compete ... will be considered by the Milwaukee Common Council, AT&T would ... by the service. , , While there are ...
... big business (untold billions of dollars every year), they also ... of the fundamental ethical principle of informed consent ... is that conducting a clinical trial carries with it the ... positive or negative or even if the clinical trial is ...
... For the second time this year, a tech-based company in ... to the public. Called an initial public offering, this kind ... and investors who are directly involved, but to others who ... Madison-based biotechnology company, has filed papers with the Securities ...
Cached Biology Technology:State video franchises vs. universal service: Grasping the total picture 2State video franchises vs. universal service: Grasping the total picture 3State video franchises vs. universal service: Grasping the total picture 4What patients want: A story of choice, clinical trials & evidence-based medicine 2What patients want: A story of choice, clinical trials & evidence-based medicine 3What patients want: A story of choice, clinical trials & evidence-based medicine 4What patients want: A story of choice, clinical trials & evidence-based medicine 5Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3
(Date:10/22/2014)... The Nano-Bio Manufacturing Consortium (NBMC), an industry-academia ... (AFRL), has chosen a project proposed by the Arizona ... Arizona College of Medicine – Tucson ... is to assess different sweat collection methods and devices ... under a variety of human-body conditions, the results of ...
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/18/2014)... undiagnosed, suspected genetic conditions, a certain type of exome ... yield than traditional molecular diagnostic methods, according to a ... being released to coincide with the American Society of ... the protein­coding region of the genome (the complete set ... or organism), has been rapidly applied in research settings ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Improved electricity access has little impact on climate change 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... The next time you are stung by a ... venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs ... or diagnose cancer. This research, described in the August ... ( http://www.fasebj.org ), shows how modified melittin may revolutionize ...
... by which Helicobacter pylori , the only known cancer-causing ... The new study, in the journal Oncogene , reports ... pylori infection and stomach cancer, the second leading cause ... population is infected with H. pylori, a bacterium that can ...
... genomes that potentially hide a rich array of pharmaceutical ... antibiotic. The study, reported in the August issue of ... serious diseases that are rapidly acquiring multi-drug resistance. ... successfully used a ,genome mining, approach to find and ...
Cached Biology News:Cancer-causing bacterium targets tumor-suppressor protein 2Cancer-causing bacterium targets tumor-suppressor protein 3Mining bacterial genomes reveals valuable 'hidden' drugs 2
Ets-1...
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: